UOC
SIOX

UBS O'Connor’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

UBS O'Connor’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-125,000
Closed -$1.33M – 308
2019
Q1 		$1.33M Buy
+125,000
New +$1.24M 0.04% 169

Other funds holding SIOX

SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS O'Connor's SIOX Position: Q2 2019 in Review

UBS O'Connor sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2019, closing a stake of 125,000 shares — an estimated $1.33M sold.

UBS O'Connor first reported a position in SIOX in Q1 2019 and held it in 1 quarter. The position peaked at $1.33M in Q1 2019. 39 funds tracked by Wall St. Rank hold SIOX as of Q2 2019.

  • UBS O'Connor reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • UBS O'Connor sold 125,000 Sio Gene Therapies Inc. Common Stock shares in Q2 2019, an estimated $1.33M.
  • UBS O'Connor first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • UBS O'Connor's Sio Gene Therapies Inc. Common Stock position peaked at $1.33M in Q1 2019.
  • 39 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2019.

Based on UBS O'Connor's 13F filing for Q2 2019, filed 14 Aug 2019.